A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

Dermatology

The efficacy and safety of Lirentelimab in adults with moderate to severe Atopic Dermatitis.

Sponsor(s)
Allakos Inc.
Principal Investigator(s)
Dr. Jonathan Silverberg MD, PHD, MPH
Request Information
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.